MCID: DNG005
MIFTS: 55

Dengue Virus

Categories: Genetic diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Dengue Virus

MalaCards integrated aliases for Dengue Virus:

Name: Dengue Virus 57
Dengue Fever, Protection Against 57 13 6
Dengue Virus, Susceptibility to 57 29 40
Dengue Fever 59 73
Dengue Virus Infection 59
Df 59

Characteristics:

Orphanet epidemiological data:

59
dengue fever
Prevalence: >1/1000 (Worldwide),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

OMIM 57 614371
Orphanet 59 ORPHA99828
ICD10 via Orphanet 34 A97.2 A97.9 A97.0 more
UMLS via Orphanet 74 C0376300 C0011311 C0019100
MESH via Orphanet 45 D003715

Summaries for Dengue Virus

OMIM : 57 Dengue virus is a flavivirus belonging to the family Flaviviridae. Its principal vector is Aedes aegypti, a highly urbanized, daytime-biting mosquito that breeds in stored water. There are 4 antigenetically variant serotypes of dengue virus, DEN-1 to DEN-4, and type-specific immunity against one serotype cannot block infection with another serotype. Disease manifestations following dengue infection range from subclinical infection to severe and fatal disease, with age, gender, genotype, immunologic status, and flavivirus infection history of the host all influencing disease severity. Primary infection is mainly associated with dengue fever (DF). Symptoms of DF typically appear 4 to 7 days after the mosquito bite and include high fever, headache, retroocular pain, conjunctival changes, and facial flushing. Although primary dengue infections are mostly recovered, a secondary infection with a different serotype of the virus leads to the complex condition of dengue hemorrhagic fever (DHF) with plasma leakage and thrombocytopenia or a more fatal condition, dengue shock syndrome (DSS). High fever, hemorrhagic phenomenon, hepatomegaly, and circulatory failure are mainly associated with DHF. Hemorrhages in DHF are seen in skin, subcutaneous tissues, heart, liver, and gastrointestinal tract. An estimated 50 to 100 million illnesses due to dengue infection occur annually, including 250,000 to 500,000 cases of DHF and 24,000 deaths. About 2.5 billion people are estimated to be at risk, particularly those living in tropical and subtropical areas of Asia and Latin America (reviews by Faheem et al. (2011), Whitehorn and Simmons (2011), and Guzman et al. (2010)). (614371)

MalaCards based summary : Dengue Virus, also known as dengue fever, protection against, is related to japanese encephalitis and rift valley fever, and has symptoms including fever and pruritus. An important gene associated with Dengue Virus is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and skin, and related phenotypes are nausea and vomiting and hypotension

Wikipedia : 76 Dengue virus (DENV) is the cause of dengue fever. It is a mosquito-borne single positive-stranded RNA... more...

Related Diseases for Dengue Virus

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 japanese encephalitis 30.9 CD209 DDX58
2 rift valley fever 30.4 CD209 IFITM3
3 encephalitis 30.2 CD209 DDX58 RPSA RSAD2
4 chikungunya 30.1 DDX58 OAS3 RSAD2
5 tick-borne encephalitis 29.9 CD209 OAS3
6 herpes simplex 29.5 CD209 DDX58 IFIH1
7 hepatitis 29.3 CLDN1 DDX58 HAVCR1
8 influenza 27.6 DDX58 IFIH1 IFITM1 IFITM2 IFITM3 RSAD2
9 west nile virus 26.3 CD209 DDX58 EXOC1 IFIH1 IFITM1 IFITM2
10 dengue disease 12.1
11 dengue shock syndrome 11.5
12 dengue hemorrhagic fever 11.4
13 asymptomatic dengue 11.2
14 singleton-merten syndrome 10.4 DDX58 IFIH1
15 endotheliitis 10.4
16 hemorrhagic fever 10.4
17 measles 10.1 CD209 DDX58 IFIH1
18 viral infectious disease 10.1 CD209 DDX58 IFIH1
19 thrombocytopenia 10.1
20 yellow fever 10.0
21 type i 10.0
22 st. louis encephalitis 9.9
23 myelitis 9.9
24 transverse myelitis 9.9
25 vaccinia 9.9
26 myositis 9.8
27 neuroblastoma 9.8
28 leukemia 9.8
29 zika fever 9.8
30 scrub typhus 9.8
31 cholecystitis 9.8
32 acalculous cholecystitis 9.8
33 virus associated hemophagocytic syndrome 9.8
34 zika virus infection 9.8
35 hemophagocytic syndrome associated with an infection 9.8
36 microphthalmia with limb anomalies 9.7 OAS3 STAT2
37 stomatitis 9.7 DDX58 IFITM2 IFITM3 RSAD2
38 thrombocytopenia, cyclic 9.6
39 malaria 9.6
40 hepatitis b 9.6
41 mucositis 9.6
42 parotitis 9.6
43 respiratory failure 9.6
44 optic neuritis 9.6
45 crimean-congo hemorrhagic fever 9.6
46 coccidioidomycosis 9.6
47 neuritis 9.6
48 melanoma 9.6
49 leptospirosis 9.6
50 cervicitis 9.6

Graphical network of the top 20 diseases related to Dengue Virus:



Diseases related to Dengue Virus

Symptoms & Phenotypes for Dengue Virus

Clinical features from OMIM:

614371

Human phenotypes related to Dengue Virus:

59 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 59 Occasional (29-5%)
2 hypotension 59 Occasional (29-5%)
3 hepatomegaly 59 Occasional (29-5%)
4 fever 59 Very frequent (99-80%)
5 arthralgia 59 Frequent (79-30%)
6 ascites 59 Occasional (29-5%)
7 abdominal pain 59 Frequent (79-30%)
8 pruritus 59 Frequent (79-30%)
9 thrombocytopenia 59 Occasional (29-5%)
10 gastrointestinal hemorrhage 59 Occasional (29-5%)
11 diarrhea 59 Occasional (29-5%)
12 epistaxis 59 Occasional (29-5%)
13 skin rash 59 Frequent (79-30%)
14 bruising susceptibility 59 Occasional (29-5%)
15 gingival bleeding 59 Occasional (29-5%)
16 petechiae 59 Occasional (29-5%)
17 lethargy 59 Occasional (29-5%)
18 headache 59 Very frequent (99-80%)
19 cerebral hemorrhage 59 Occasional (29-5%)
20 leukopenia 59 Occasional (29-5%)
21 hypoproteinemia 59 Occasional (29-5%)
22 cardiorespiratory arrest 59 Occasional (29-5%)

UMLS symptoms related to Dengue Virus:


fever, pruritus

Drugs & Therapeutics for Dengue Virus

Drugs for Dengue Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Anti-Allergic Agents Phase 4
4 Antipruritics Phase 4
5 Dermatologic Agents Phase 4
6 Histamine Antagonists Phase 4
7 Histamine H1 Antagonists Phase 4
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Neurotransmitter Agents Phase 4
10 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
13
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
14 Antibodies Phase 1, Phase 2,Phase 2,Not Applicable
15 Immunoglobulins Phase 1, Phase 2,Phase 2,Not Applicable
16
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
17
Aluminum sulfate Approved Phase 1 10043-01-3
18 Adjuvants, Immunologic Phase 1
19 Antacids Phase 1
20 Anti-Ulcer Agents Phase 1
21 Gastrointestinal Agents Phase 1
22
Albendazole Approved, Vet_approved Not Applicable 54965-21-8 2082
23
Ivermectin Approved, Investigational, Vet_approved Not Applicable 70288-86-7 6474909
24
Mebendazole Approved, Vet_approved Not Applicable 31431-39-7 4030

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Recruiting NCT02555072 Phase 4
3 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Unknown status NCT01373281 Phase 3
4 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Unknown status NCT01374516 Phase 3
5 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
6 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
7 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
8 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
9 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
10 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Recruiting NCT03342898 Phase 3
11 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Recruiting NCT03341637 Phase 3
12 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
14 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
15 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
16 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine Not yet recruiting NCT03525119 Phase 3
17 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
18 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
19 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
20 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
21 A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children Completed NCT01843621 Phase 1, Phase 2
22 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
23 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
24 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
25 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
26 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
27 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
28 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
29 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
30 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
31 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
32 Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults Recruiting NCT02421367 Phase 1, Phase 2
33 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Recruiting NCT03110770 Phase 2
34 A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan Recruiting NCT03485144 Phase 2
35 Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh Active, not recruiting NCT02678455 Phase 2
36 Immunogenicity and Safety of 3-Dose and Booster Dose of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
37 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
38 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
39 Safety and Immunogenicity of Takeda's TDV in Healthy Children Active, not recruiting NCT02948829 Phase 2
40 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
41 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
42 Safety and Immune Response to an Investigational Dengue Type 2 Vaccine Completed NCT01073306 Phase 1
43 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01436422 Phase 1
44 Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01072786 Phase 1
45 Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults Completed NCT01931176 Phase 1
46 Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine Completed NCT02684383 Phase 1
47 Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Completed NCT01084291 Phase 1
48 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01506570 Phase 1
49 Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults Completed NCT02392325 Phase 1
50 A Study of Balapiravir in Patients With Dengue Virus Infection Completed NCT01096576 Phase 1 balapiravir [RO4588161];placebo

Search NIH Clinical Center for Dengue Virus

Genetic Tests for Dengue Virus

Genetic tests related to Dengue Virus:

# Genetic test Affiliating Genes
1 Dengue Virus, Susceptibility to 29 CD209

Anatomical Context for Dengue Virus

MalaCards organs/tissues related to Dengue Virus:

41
Testes, Liver, Skin, Endothelial, Heart, Monocytes, T Cells

Publications for Dengue Virus

Articles related to Dengue Virus:

(show top 50) (show all 679)
# Title Authors Year
1
Comparison of reverse-transcriptase qPCR and droplet digital PCR for the quantification of dengue virus nucleic acid. ( 29398345 )
2018
2
Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome. ( 29447178 )
2018
3
Ex Vivo ELISpot Assay to Investigate Dengue Virus Specific T-Cell Responses. ( 29956183 )
2018
4
Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus. ( 29928270 )
2018
5
Dynamic remodeling of lipids coincides with dengue virus replication in the midgut of Aedes aegypti mosquitoes. ( 29447265 )
2018
6
Long-term stability of antibody responses elicited by Dengue virus envelope DIII-based DNA vaccines. ( 29923817 )
2018
7
Dengue Virus Induces the Release of sCD40L and Changes in Levels of Membranal CD42b and CD40L Molecules in Human Platelets. ( 29976871 )
2018
8
Renal manifestations of dengue virus infections. ( 29414180 )
2018
9
Aedes anphevirus (AeAV): an insect-specific virus distributed worldwide in <i>Aedes aegypti</i> mosquitoes that has complex interplays with <i>Wolbachia</i> and dengue virus infection in cells. ( 29950416 )
2018
10
Erratum: Publisher Correction: A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. ( 29424838 )
2018
11
Immune response-related genes associated to blocking midgut dengue virus infection in Aedes aegypti strains that differ in susceptibility. ( 29389079 )
2018
12
First detection of dengue virus in the saliva of immunocompetent murine model. ( 29412340 )
2018
13
Proposing drug fragments for dengue virus NS5 protein. ( 29945503 )
2018
14
C5a receptor targeting of partial non-structural protein 3 of dengue virus promotes antigen-specific IFN-I^-producing T-cell responses in a mucosal dengue vaccine model. ( 29397905 )
2018
15
Complete Genome Sequence of Dengue Virus Serotype 2, Asian/American Genotype, Isolated from the Urine of a Venezuelan Child with Hemorrhagic Fever in 2016. ( 29903824 )
2018
16
Complete Genome Sequence Analysis of an Imported Dengue Virus Serotype 1 Strain from Myanmar. ( 29976608 )
2018
17
Post Dengue Fever Epidural abscess with or without Spondylodiscitis-a Case series of 8 patients in a single season in a single Centre: Do the dengue has a predilection for the Neural tissue? ( 29979359 )
2018
18
Validation of POCKITa8c Dengue Virus Reagent Set for Rapid Detection of Dengue Virus in Human Serum on a Field-Deployable PCR System. ( 29436418 )
2018
19
Cloning and Expression of NS3 Gene of Pakistani Isolate Type 2 Dengue Virus. ( 29978123 )
2018
20
Development of peptide-based chemiluminescence enzyme immunoassay (CLEIA) for diagnosis of dengue virus infection in human. ( 29966589 )
2018
21
Competitive suppression of dengue virus replication occurs in chikungunya and dengue co-infected Mexican infants. ( 29970133 )
2018
22
Complete Coding Sequences of Five Dengue Virus Type 2 Clinical Isolates from Venezuela Obtained through Shotgun Metagenomics. ( 29930056 )
2018
23
Transcytosis Involvement in Transport System and Endothelial Permeability of Vascular Leakage during Dengue Virus Infection. ( 29419739 )
2018
24
Selective Tropism of Dengue Virus for Human Glycoprotein Ib. ( 29426910 )
2018
25
Spatial-Temporal Analysis of Dengue Fever and Hemorrhagic Fever in Mexico from 1995-2015. ( 29402463 )
2018
26
Inhibitory effect of the green tea molecule EGCG against dengue virus infection. ( 29429035 )
2018
27
Molecular characterization of an imported dengue virus serotype 4 isolate from Thailand. ( 29948381 )
2018
28
Longitudinally extensive transverse myelitis following dengue virus infection: A rare entity. ( 29536963 )
2018
29
Posaconazole inhibits dengue virus replication by targeting oxysterol-binding protein. ( 29981375 )
2018
30
Travel-acquired Scrub Typhus Infection Masked by Dengue Fever in a Patient from Nonendemic Area. ( 29910575 )
2018
31
Seroprevalence of Dengue Virus, West Nile Virus, Chikungunya Virus, and Zika Virus in International Travelers Attending a Travel and Migration Center in 2015-2017, Southern Italy. ( 29683399 )
2018
32
Arthropod EVs mediate dengue virus transmission through interaction with a tetraspanin domain containing glycoprotein Tsp29Fb. ( 29946031 )
2018
33
Cultured ELISpot Assay to Investigate Dengue Virus Specific T-Cell Responses. ( 29956182 )
2018
34
Ocular manifestations of emerging arboviruses: Dengue fever, Chikungunya, Zika virus, West Nile virus, and yellow fever. ( 29929827 )
2018
35
Imported case of Dengue virus 3 genotype I in Rio de Janeiro state, Brazil. ( 29947712 )
2018
36
Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia. ( 29953438 )
2018
37
Anaplerotic Role of Glucose in the Oxidation of Endogenous Fatty Acids during Dengue Virus Infection. ( 29404419 )
2018
38
The spatial and temporal scales of local dengue virus transmission in natural settings: a retrospective analysis. ( 29394906 )
2018
39
Dengue virus infection among long-term travelers from the Netherlands: A prospective study, 2008-2011. ( 29415063 )
2018
40
The epidemiological characteristics and molecular phylogeny of the dengue virus in Guangdong, China, 2015. ( 29967414 )
2018
41
Estimating the actual importation risk of dengue virus infection among Japanese travelers. ( 29924819 )
2018
42
A Global Interactome Map of the Dengue Virus NS1 Identifies Virus Restriction and Dependency Host Factors. ( 29386121 )
2018
43
Engineered Dengue Virus Domain III Proteins Elicit Cross-neutralizing Antibody Responses in Mice. ( 29976679 )
2018
44
Inhibition of dengue virus infection by small interfering RNAs that target highly conserved sequences in the NS4B or NS5 coding regions. ( 29392497 )
2018
45
Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: a systematic review. ( 29391071 )
2018
46
Comparative proteomics reveals that YK51, a 4-Hydroxypandurantin-A analogue, downregulates the expression of proteins associated with dengue virus infection. ( 29404200 )
2018
47
Dengue Virus NS1 Protein as a Diagnostic Marker: Commercially Available ELISA and Comparison to qRT-PCR and Serological Diagnostic Assays Currently Used by the State of Florida. ( 28740517 )
2017
48
Endoplasmic Reticulum Protein SCAP Inhibits Dengue Virus NS2B3 Protease by Suppressing Its K27-Linked Polyubiquitylation. ( 28228593 )
2017
49
Vitamin D serostatus and dengue fever progression to dengue hemorrhagic fever/dengue shock syndrome. ( 28903788 )
2017
50
Dengue virus NS1 protein activates immune cells via TLR4 but not TLR2 or TLR6. ( 28220810 )
2017

Variations for Dengue Virus

ClinVar genetic disease variations for Dengue Virus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CD209 CD209, -336A-G single nucleotide variant protective,risk factor

Expression for Dengue Virus

Search GEO for disease gene expression data for Dengue Virus.

Pathways for Dengue Virus

GO Terms for Dengue Virus

Cellular components related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.77 CD209 CLDN1 CLEC5A DDX58 EXOC1 HAVCR1
2 plasma membrane GO:0005886 9.4 CD209 CLDN1 CLEC5A DDX58 EXOC1 IFITM1

Biological processes related to Dengue Virus according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 viral entry into host cell GO:0046718 9.85 CD209 CLDN1 CLEC5A HAVCR1 MRC1 RPSA
2 type I interferon signaling pathway GO:0060337 9.8 IFITM1 IFITM2 IFITM3 OAS3 RSAD2 STAT2
3 response to virus GO:0009615 9.8 DDX58 IFIH1 IFITM1 IFITM2 IFITM3 OAS3
4 cellular response to interferon-gamma GO:0071346 9.78 CLDN1 LGALS9 MRC1
5 response to interferon-gamma GO:0034341 9.73 C19orf66 IFITM1 IFITM2 IFITM3
6 positive regulation of interleukin-6 secretion GO:2000778 9.72 DDX58 IFIH1 LGALS9
7 negative regulation of viral entry into host cell GO:0046597 9.71 IFITM1 IFITM2 IFITM3
8 response to biotic stimulus GO:0009607 9.7 IFITM1 IFITM2 IFITM3
9 viral process GO:0016032 9.7 CD209 CLDN1 CLEC5A DDX58 EXOC1 HAVCR1
10 positive regulation of tumor necrosis factor secretion GO:1904469 9.69 DDX58 IFIH1 LGALS9
11 response to interferon-alpha GO:0035455 9.65 IFITM1 IFITM2 IFITM3
12 negative regulation of type I interferon production GO:0032480 9.63 DDX58 IFIH1
13 response to interferon-beta GO:0035456 9.63 IFITM1 IFITM2 IFITM3
14 negative regulation of viral genome replication GO:0045071 9.63 C19orf66 IFITM1 IFITM2 IFITM3 OAS3 RSAD2
15 positive regulation of interferon-beta production GO:0032728 9.62 DDX58 IFIH1
16 cellular response to exogenous dsRNA GO:0071360 9.62 DDX58 IFIH1
17 positive regulation of interferon-alpha production GO:0032727 9.61 DDX58 IFIH1
18 positive regulation of interferon-alpha secretion GO:1902741 9.6 DDX58 IFIH1
19 positive regulation of response to cytokine stimulus GO:0060760 9.59 DDX58 IFIH1
20 detection of virus GO:0009597 9.58 DDX58 IFIH1
21 positive regulation of interferon-beta secretion GO:0035549 9.58 DDX58 IFIH1
22 regulation of type III interferon production GO:0034344 9.57 DDX58 IFIH1
23 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.56 DDX58 IFIH1
24 defense response to virus GO:0051607 9.32 C19orf66 DDX58 EXOC1 IFIH1 IFITM1 IFITM2
25 innate immune response GO:0045087 10.06 CD209 CLEC5A DDX58 IFIH1 IFITM1 IFITM2
26 immune system process GO:0002376 10.04 CD209 CLEC5A DDX58 IFIH1 IFITM1 OAS3

Molecular functions related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.46 CD209 CLEC5A LGALS9 MRC1
2 mannose binding GO:0005537 9.26 CD209 MRC1
3 double-stranded RNA binding GO:0003725 9.13 DDX58 IFIH1 OAS3
4 virus receptor activity GO:0001618 9.1 CD209 CLDN1 CLEC5A HAVCR1 MRC1 RPSA

Sources for Dengue Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....